

July 17, 2025

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Receipt of Inspection Report of European Union Good Manufacturing Practice (EU GMP) Audit conducted for the manufacturing unit situated at Surat Special Economic Zone

Ref.: Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we, Zota Health Care Limited (the "Company") would like to inform you that the EU GMP Audit has been conducted at Company's Manufacturing Plant situated at Surat Special Economic Zone, Sachin, Surat, Gujarat from May 06, 2025 to May 09, 2025 and on the basis of verification of facilities available in plant and inspection report; the Company concluded the aforementioned EU GMP audit with 0 (zero) Critical Observations, 16 (sixteen) Major observations and 8 (Eight) Other Observations.

Following the audit, the Company is in process of initiating the requisite Corrective measures and shall submit corrective action plan within 20 (twenty) days. The Company shall submit detailed response along with the evidences of the implemented actions to the said Regulatory Authority within 30 days (for major observations) and 60 days (for other observations) of such audit. Subsequent, to satisfactory resolution of all observations and receipt of EU GMP approval, the Company will start export of its products in European countries.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya (Company Secretary & Compliance Officer)

Place: Surat

Registered Office:

Zota House, 2/896, Hira Modi Street,

Sagrampura, Surat-395002 Ph: +91 261 2331601

Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352